NKGen Biotech is conducting numerous clinical trials to discover how natural killer (NK) cells can help patients with cancer and neurodegenerative conditions.

SNK01, NKGen Biotech’s autologous NK cell therapy candidate, has active and planned clinical trials in several therapeutic areas, including oncology and neurodegeneration. This approach allows us to evaluate the potential benefits of adoptive cellular immunotherapy for multiple biologically relevant disease areas. SNK02, NKGen’s allogeneic NK cell therapy, received IND clearance in Q4 2022 to commence a phase I study in solid tumors which is expected to start in first half of 2023.




Phase I

Phase II

Phase III


– Refractory Solid Tumors, Phase l
– Neurodegenerative Disease, Phase l

Refractory Solid Tumors
Neurodegenerative Disease

SNK01 +


– Stage IV Non-small Cell Lung Cancer, Phase ll

avelumab or pembrolizumab

– Refractory PD-L1+ AND PD-L1- Solid Tumors 2, Phase l


– EGFR+ Solid Tumors, Phase l

Stage IV Non- Small Cell Lung Cancer
Refractory PD-L1+ and PD-L1- Solid Tumors *
EGFR+ Solid Tumors

Allogeneic SNK

Not Disclosed

Not Disclosed


Not Disclosed

Not Disclosed

* Following the data from our Phase 1 trial, with FDA consent, we expanded the Phase 1 trial to include a fourth cohort in refractory tumors with SNK in combination with avelumab or pembrolizumab.